From August 1987 to March 1995, 25 patients with high-grade B cell non-Hodgkin's lymphoma (NHL) were treated with high-dose therapy (HDT) followed by bone marrow purged with immunomagnetic beads. At the time of transplantation, 20 patients were in sensitive relapse and five in first complete or partial remission. Ten patients had secondary high-grade NHL transformed from low-grade NHL. The HDT consisted of TBI followed by high-dose cyclophosphamide. All patients engrafted, except for two patients with early treatmentrelated death. Eleven patients relapsed, of whom nine died of lymphoma, and two are alive in new CR. The estimated event-free and overall survivals at 5 years were 40% and 48%, respectively, with a median followup of 48 months (range 1-123). Eight of the tumours contained the translocation t(14;18) at the major breakpoint region (MBR) of BCL-2. In these patients the presence of tumour cells in the bone marrow graft before and after purging were assessed by PCR. Four of five patients infused with non-detectable minimal residual disease in their autografts are in complete remission, while two of three patients reinfused with t(14;18) positive cells after purging, experienced a fast and aggressive relapse. As found by others, our data suggest that reinfusion of tumour-free autografts obtained by efficient in vivo purging using chemotherapy before harvesting, and/or by in vitro purging of the stem cell products, influence the patients remission status after HDT. Keywords: high-grade non-Hodgkin's lymphoma; autologous bone marrow transplantation; ABMT; immunomagnetic purging Combination chemotherapy cures 30-50% of patients with high-grade non-Hodgkin's lymphoma, (NHL).
salvage chemotherapy regimens are able to induce longterm survival in only 5-10% of them. [1] [2] [3] High-dose chemotherapy (HDC) with or without total body irradiation (TBI) followed by support of autologous haematopoietic stem cells has been increasingly used in lymphoma patients. Several retrospective studies have shown that ABMT induces higher response rates than conventional therapy when used as salvage therapy for patients with relapsed high-grade lymphoma 2, 4, 5 These results have been further confirmed in a randomised study, 6 and HDT is now recommended for patients in chemosensitive first or subsequent relapse. 7 The major problem after HDT is relapse of lymphoma either due to residual tumour in the patients and/or reinfusion of an autograft contaminated with tumour cells. In low-grade lymphomas, one study showed that patients receiving autografts negative for the translocation t (14, 18) after purging had increased disease-free survival. 8 In intermediate and high-grade lymphoma, others have shown that the presence of tumour cells in the bone marrow at harvest is associated with poor survival. 9 Several methods have therefore been developed in order to reduce the number of tumour cells in the autografts. [10] [11] [12] The immunomagnetic purging procedure has been developed at The Norwegian Radium Hospital. 13 This method could remove 5 log of malignant B cells in an experimental system, and was more efficient compared with antibody complement-mediated cell lysis. 14 The immunomagnetic method has been scaled up for clinical use, and the purging efficacy was demonstrated in patients with follicular lymphomas. 15 The immunomagnetic purging of autografts has since been applied in patients with various B cell neoplasias. [16] [17] [18] To our knowledge, immunomagnetic purging has not been systematically tested in high-grade B cell lymphomas. In order to examine the feasibility of immunomagnetic purging with regard to survival and engraftment, 25 patients were treated with HDT followed by ABMT with bone marrow purged with immunomagnetic beads. Although it was found by immunocytochemistry (ICC) that immunomagnetic beads removed all B cells present in the autografts, the sensitivity is too low to detect minimal residual disease (MRD). The translocation t(14;18) at the major breakpoint region (MBR) of BCL-2 is a highly specific clonal marker. This translocation is most frequently found in low-grade lymphomas, but can also be present in high-grade grade B cell lymphomas in up to 30% of cases. 19, 20 Tumour tissue from all of the patients was examined with regard to MBR posi-tivity, and eight out of 25 (32%) tumours were positive. In these patients, we further evaluated the presence of tumour cells in the bone marrow grafts before and after purging, as well as in the immunomagnetic bead fraction by PCR.
Our study has shown that immunomagnetic purging does not have a negative influence on haematopoietic reconstitution. The survival data were similar to that shown in other studies, and in spite of the limited number of patients with t(14;18)-positive tumours, our results indicate a positive association between relapse and the presence of minimal residual tumour cells in the reinfused autograft.
Materials and methods

Patient characteristics and treatment before ABMT
Between November 1987 and January 1995, 25 patients with high-grade B cell NHL were included in a phase II study and treated with HDT and ABMT. Our inclusion criteria were patients who had failed to achieve CR after a first-line combination chemotherapy regimen and patients with chemosensitive first or subsequent relapse, age less than 60 years, WHO performance status р1, normal cardial, hepatic and renal function. The initial characteristics of the patients are listed in Table 1 . Fifteen men and 10 women with a median age at ABMT of 42 years (range 15-59) were included. All tumour tissues were classified according to the Revised European American Classification of Lymphoid Neoplasms (REAL). 21 Ten of the patients had lymphoma that had undergone histologic transformation from a low-grade to a high-grade NHL, median 31.5 months (range 1-120) after diagnosis. Eleven patients had bone marrow involvement; five at diagnosis, four both at diagnosis and relapse, and two at relapse only ( Table 1) .
The patients received a median number of 12 (range 6-21) combination chemotherapy cycles before ABMT, which indicates that most of the patients were heavily treated before transplantation. First-line therapy was CHOP or CHOP-like combinations and chlorambucil and prednisone for patients with initial low-grade histologies. Salvage and induction chemotherapy to test for chemosensitivity before HDT was MIME 3 in the majority of cases. Five patients received local involved-field radiation therapy.
All of the patients had chemosensitive tumours. Five patients were slow responders and were offered transplantation in first CR or first PR after receiving more than one combination chemotherapy regimen. The other patients all had sensitive relapses; four relapsed patients achieved only a PR to the induction regimen prior to ABMT. Two of these patients had persistent bone marrow involvement estimated by immunohistological examination of bone marrow biopsies at harvest. The other patients were transplanted in second and third CR. The protocol was approved by the local ethics committee. Informed consent for participation in the study was obtained from all patients.
Immunobeads and monoclonal antibodies
The combination of antibodies used for purging with immunomagnetic beads was selected on the basis of antigen expression by the individual B cell lymphomas. The anti-CD19, CD20, CD22, CD23, CD37 monoclonal antibodies of IgG subtypes were provided by Baxter Biotech, Deutschland, Immunotherapy Division, Munich, Germany. Dynabeads M-450, directly coated with the IgM MoAbs anti-CD10, anti-CD19 (AB1) and the anti HLA-DR (AB4), and Dynabeads M-450 Sheep anti-Mouse IgG, were supplied by Dynal, Oslo, Norway.
Bone marrow harvest and immunomagnetic purging
Bone marrow was obtained by multiple aspirations from the iliac crests and sternum under general anaesthesia. Mononuclear cell (MNC) fractions were prepared either by the use of a 2991 Cobe Cell Processor (Lakewood, CO, USA) and Ficoll (Lymphoprep; Nycomed, Oslo, Norway) or a special program designed for making bone marrow mononuclear cells without Ficoll in a CS-3000 Plus Blood Cell Separator (Baxter Healthcare Corporation, Fenwal Division, Deerfield, IL, USA).
The purging procedure 22 with immunomagnetic beads is described elsewhere. Briefly, the phenotype and total number of antibody-binding cells in the bone marrow were determined in advance by flow cytometry. Based on these data mononuclear bone marrow cells were incubated at 4°C for 30 min with a mixture of the selected monoclonal antibodies (10 g of each per 1 ϫ 10 6 antigen-binding cells); the anti-CD19, CD20, CD22, CD23, CD37 monoclonal antibodies. Excess antibody was removed by washing the bone marrow cells twice with cold medium. Sheep antimouse (SAM) beads were added to give a ratio of beads/total nucleated cells of 2 to 1. The bead/cell rosettes and excess beads were removed using our own purging device 22 or the Fenwall, Max Sep, Magnetic Cell Separator (Baxter Healthcare Corporation). After a second cycle of purging, in which the same amount of SAM-beads was added, the cell suspension was concentrated and frozen, employing a controlled rate freezer (Planer Kryo 10; Planer, Middlesex, UK). To avoid the time consuming two-step procedure with antibody incubation followed by SAM beads, three patients had their bone marrow purged with a mixture of three types of immunobeads coated with the IgM antibodies anti-CD10, -CD19 and -HLA-DR, respectively. The prepared immunobeads were added directly to the bone marrow and the bead/cell rosettes were removed by the method as described previously.
Haemopoietic progenitor cell assay
The clonogenic capacity of treated and untreated haemopoietic progenitor cells was assessed in the granulocytemacrophage colony-forming unit (CFU-GM) assay, as previously described. 13 Each assay was performed with triplicate 1 ml cultures in 35 mm dishes at 37°C in a 5% CO 2 , 100% humidified atmosphere. After 14 days of incubation, colonies were counted by use of an inverse phase contrast microscope. 13 
PCR
DNA was extracted from diagnostic biopsies from frozen and/or formalin-fixed paraffin embedded tissue in 25 patients using conventional methods. Only patients who had lymphomas with detectable malignant clones by PCR study for BCL-2 were included for further PCR studies. DNA was also extracted from bone marrow aspirate samples before and after purging, as well as from the bead fraction. From bone marrow samples, DNA was extracted by Qiagen QIAamp Blood Kit (Hilden, Germany) and from bead fractions with Dynabeads DNA direct from Dynal.
PCR amplification was used to detect the MBR breakpoint. A semi-nested reaction was performed with the following primers: JH (5ЈACC TGA GGA GAC GGT GAC C 3Ј), MBR-I (5ЈTAT GGT GGT TTG ACC TTT AG 3Ј), in the first round and JH and MBR-II (5Ј GAG AGT TGC TTT ACG TGG CCT 3Ј) in the second round. The first round of the PCR was performed in a total volume of 50 l containing 25 mm each of dATP, dCTP, dGTP and dTTP, 0.4 nm each of oligonucleotide primers, 1.25 mm MgCl 2 , 1.25 U Ampli Taq GOLD polymerase in PCR buffer and 100 ng DNA extract or scrapings from the half of the cytospin preparations that were added to the PCR tubes. The first PCR consisted of one cycle at 94°C for 10 min, followed by 20 cycles at 94°C for 15 s, 56°C for 15 s and 72°C for 30 s and one final cycle at 72°C for 8 min. The second round PCR was performed with the same mastermix concentration and 1 l of the first PCR reaction as template. The setting for the second round was the same except there were 35 cycles and the annealing temperature was 57°C. Generally, at least two identical reactions were run for each sample to test for reproducibility. Appropriate positive and negative controls were included with each run. Specific products were between 110 and 280 bp. The sensitivity for the MBR reaction was tested with Karpas 422 DNA diluted in DNA from white blood cells collected from healthy blood donors. The sensitivity was 10
Ϫ5
. The specificity of products was confirmed by hybridization with an internal oligonucleotide probe (5Ј CAA CAC AGA CCC ACC CAG AGC 3Ј) as described previously. 23 To confirm negative results, all negative samples were repeated at least once, and the presence of amplifiable DNA was confirmed by PCR for DQA1, as previously described. 24 
High-dose treatment
Total body irradiation (TBI) was given before chemotherapy (1.3 Gy ϫ10) twice daily during 5 consecutive days (day Ϫ8 to day Ϫ4). The total dose was 13 Gy and the dose rate was approximately 60 mGy per min in midplane during irradiation. The doses to the lungs were reduced to 11 Gy with lungshields. On each of 2 consecutive days (day Ϫ3, day Ϫ2) cyclophosphamide, 60 mg per kilogram of body weight, was infused. On day 0, the purged bone marrow cells were thawed rapidly in a 37°C waterbath and reinfused through a central venous double lumen Hickman catheter.
Post-transplantation treatment
In addition to the HDT, four patients who entered transplantation with clinical or radiological evidence of disease, received involved-field radiotherapy (30-33.6 Gy) within 6 to 9 weeks after ABMT.
Evaluation and response criteria
Before ABMT, all patients underwent physical examination, chest radiography, abdominal and pelvic CT scanning (and chest CT scanning if indicated), ultra sound of upper abdomen and liver/spleen and bone marrow biopsy.
CR was defined as the complete disappearance of all measurable radiographic or clinical evidence of disease. PR was defined as a reduction in tumour mass by more than 50%, measured as the sum of the product of the two largest perpendicular diameters of the tumours. Progression was defined as at least 25% increase in previously noted tumour mass or the appearance of any new lesion. Response of the disease to the HDT was assessed 3 months after bone marrow reinfusion. Routine follow-up with restaging was carried out every 3 months for the first year, every 4 months for the second year, every 6 months up to 5 years and then yearly or whenever clinically indicated.
Statistical analysis
Statistical analysis was performed using the SPSS 8.0 for Windows (SPSS, Chicago, IL, USA). Analysis was performed on all data obtained as of 12 April 1999. Event-free survival (EFS) was calculated from the date of ABMT to the date of progression, treatment-related death, or date of last follow-up. Overall survival (OS) was measured from the date of ABMT to the date of death from any cause or date of last follow-up. EFS and OS were estimated using the product-limit method of Kaplan-Meier. 25 The log-rank test was used to compare the difference between survival curves. The relation of the CFU-GM content and MNC content of the bone marrow graft to the time of haematological recovery of the recipients were evaluated by linear regression analysis. P values Ͻ0.05 were considered as statistically significant.
Results
Response and survival
The estimated event-free survival for all patients at 5 years was 40% (95% confidence interval (CI) 21-59%), while the overall survival was 48% (95% CI 28-68%) with a median follow-up of 48 months (range 1-123) (Figures 1 and 2 ). There were two treatment-related deaths. One patients died of systemic fungal infection (Candida albicans) at day ϩ25, and the other died of systemic bacterial infection (Streptococcus viridans) and reactivated CMV infection at day ϩ47. Twelve patients remain alive and free of disease, with a median follow-up of 70 months (range 48-123). Two patients died of secondary malignancy, acute myelomonocytic leukaemia (AML-M4) 7 and 48 months after ABMT, respectively. Overall, 11 patients relapsed at a median of 5 months (range 2-15) after transplantation, usually at sites of previous disease, except for one patient with a central nervous system (CNS) relapse. Of the 11 patients who relapsed, three achieved a new CR with chemotherapy and irradiation. Of the patients achieving a new CR, one patient had recurrent nodal disease 7 months after ABMT, and received local radiotherapy. The second patient had a CNS relapse 13 months after ABMT, and was treated with intrathecal chemotherapy. These two patients are still alive in CR 73 and 107 months after relapse, respectively. The other patients have all died of recurrent lymphoma at a median of 7 months (range 2-32) after relapse.
Of the seven patients not in CR at transplantation, six achieved a CR after ABMT. Two died of relapse or progression after ABMT, and one died of AML-M4.
The median survival of the 10 patients with transformed low-grade NHL after transformation was 39.5 months (range 7-113) and after ABMT 33.5 months (range 1-107). Four of these 10 patients had recurrent lymphoma, two died from recurrent disease and two achieved a new CR as described above. Two patients died of treatment-related toxicity, and two of AML-M4. At present, four out of 10 of the patients with transformed histologies are in CR, median 68.5 months (range 56-107) after ABMT.
Of the 11 patients with histological verified bone marrow involvement either at diagnosis and/or at relapse, five are alive in CR. Among the remaining six patients, two relapsed in the bone marrow and other sites, one relapsed in lymph nodes only, one died of treatment-related causes, and two died of AML-M4. Of the 14 patients without bone marrow involvement, seven are alive in CR. Seven patients have died; one patient died of treatment-related cause, six died of relapse, of whom two patients had bone marrow relapses. Thus, previous bone marrow infiltration as assessed by morphology did not influence adversely either EFS or OS (P Ͼ 0.05).
Detection of MBR in bone marrow harvest by PCR and clinical outcome
Tumour tissue from eight of the patients had t(14;18) translocation assessed by PCR ( Table 2) . Three of the patients had a transformed high-grade NHL. Two of three patients with maintained residual disease after purging had a rapid relapse including the bone marrow, the third patient developed AML-M4 7 months post transplant and autopsy showed no sign of recurrent lymphoma. One patient (patient 3) relapsing 14 months after HDT had a t(14;18) PCR-negative test of the reinfused bone marrow. No relapse in the bone marrow was observed until she died 32 months later of recurrent nodal disease. The PCR reaction of the relapsed nodal tumour tissue showed exactly the same band as the original tumour. The remaining four patients reconstituted with t(14;18) PCR-negative bone marrow cells, are all in a maintained CR. Only one patient transformed from PCR positivity to negativity after purging while the other three patients were negative both before and after purging. In patients 3 and 4 ( Table 2 ) no tumour cells could be detected in the bead/cell rosettes which indicates that tumour cells were not present at the time of transplant. In patient 8, however, a positive PCR signal was observed among the bead/cell rosettes which indicates that some nondetectable PCR positive cells were present in the bone marrow prior to purging. This patient remains in CR.
Engraftment
The median number of total MNC reinfused per patient was 3.8 ϫ 10 Ϫ9 (range 2-15), and the median number of CFU-GM/kg reinfused per patient was 4.0 ϫ 10 4 (range 1.1-16). There was no statistically significant correlation between either the number of MNC or CFU-GM/kg reinfused, respectively, and the time to neutrophil or platelet engraftment (P Ͼ 0.05) ( Table 3 ). Excluding two patients who died from treatment-related toxicity, 23 patients were evaluated for neutrophil and platelet engraftment. The median time for absolute neutrophil count (ANC) recovery (Ͼ0.5 ϫ 10 9 /l) was 23 days (range 12-59), and median time for platelet recovery (Ͼ20 ϫ 10 9 /l) was 28 days (range 12-64). Ten patients received G-CSF after ABMT, starting at median day ϩ15 (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
Discussion
This is one of the larger clinical studies in patients with high-grade NHL who have received autologous bone marrow purged with immunomagnetic beads. The majority of the 25 patients were in 2nd or 3rd CR and they were uniformly treated with TBI and high-dose cyclophosphamide. The event-free survival was 40% and the overall survival was 48% with a median follow-up of 48 months. The median follow up of disease-free survivors is 70 months, and none of the patients had a relapse of lymphoma more than 15 months after ABMT, indicating that these patients are cured. 26 Even though direct comparison between studies is difficult due to variables such as patient selection, induction therapy, histologic groups, conditioning regimens and disease status at transplantation, our survival data are similar to other published studies. [27] [28] [29] [30] [31] [32] The study includes 10 patients with transformed lowgrade NHL. It is a general opinion that standard chemotherapy has poor long-term effects in these patients with a median survival of less than 1 year. 33, 34 Schouten et al 35 reported that even HDT gave poor results in patients with transformed lymphoma. We found a median survival of 39.5 months after transformation and a median survival of 68.5 months for complete responders after ABMT. These findings suggest that some patients with transformed lowgrade lymphomas can achieve long-term survival after HDT, which is consistent with other studies. 27, 31, 36 Occult clonogenic tumour cells have been detected in microscopically normal bone marrow from patients with high-grade NHL. 37, 38 These findings indicate a rationale for purging even in patients in clinical complete remission. This is further supported by gene-marking studies in leukaemias and neuroblastoma, which demonstrated that reinfusion of autografts with remaining tumour cells may contribute to relapse. 39, 40 PCR tracing of the t(14;18) is a sensitive and reproducible marker for detection of MRD in bone marrow and blood and it might also be used as a surrogate marker for purging efficacy. The t (14, 18) , however, can only be used as a tumour marker in the limited number of high-grade NHL that carry this genetic aberration. We analysed the patients' tumour material, the bone marrow samples before and after purging, as well as the 870 Moabs ϭ monoclonal antibodies; IB ϭ immunomagnetic beads; MNC ϭ mononuclear cells; CFU-GM ϭ granulocyte, macrophage colony-forming unit; G-CSF ϭ granulocyte colony-stimulating factor; ANC ϭ absolute neutrophil count; BM ϭ bone marrow.
bead fractions. Eight of the 25 patients (32%) had MBRpositive tumours (Table 2) . Even though the number of patients was small, we found a positive association between reinfusion of tumour-free or contaminated autografts and clinical outcome. Out of the three patients receiving MBRpositive harvest, two had a relapse of lymphoma. The third patient developed AML-M4. The patient (No. 1) whose autograft was purged to PCR negativity, has no evidence of relapse, which might indicate the efficacy of the purging method. In another patient (No. 8), with a PCR-negative harvest before and after purging, a positive PCR signal was found in the bead fraction. This indicates that a small number of tumour cells were present in the bone marrow before purging, that could not be detected by PCR without prior concentration in the bead fraction. Positive enrichment of tumour cells by immunomagnetic beads can therefore be applied to increase the sensitivity of the PCR for detection of MRD. A positive PCR signal in the bead fraction in four patients indicates that tumour cells were removed from the graft, but purging in two of the cases was not complete (Table 2 ). In two of the patients with morphological bone marrow infiltration at harvest, no tumour cells could be detected with ICC after purging. The result of the ICC examination in one of these patients has been described previously. 41 The t(14;18) translocation could not be detected in the tumours of these two patients, and therefore we were not able to evaluate further the purging efficacy of the harvest by PCR. Nevertheless, none of the patients experienced relapse of their lymphoma. Different factors may influence the engraftment after HDT: the source of progenitor cells used, previous chemotherapy, use of growth factors and manipulation of the stem cell product. We found no evidence that B cell purging had any adverse effect on haematological reconstitution. Our engraftment data are in accordance with other studies regarding both purged and unpurged marrow. 27, 28, 31, 32 Recently, we have also confirmed that there is no difference between purged and unpurged autografts with regard to long-term immune reconstitution after ABMT. 42 Prospective randomised studies are needed to show whether purging of the autografts contribute to better clinical outcome or not. 43 Since HDT is considered as standard treatment in chemosensitive relapsed high-grade lymphomas, it should not be controversial to suggest a clinical trial focusing on this important issue. Is, however, initiation and implementation of such a study realistic today? The experience from the EBMT-conducted CUP trial 44 in lowgrade lymphomas, which was closed because of too low patient accrual, is discouraging. New semi-quantitative PCR methods for MRD detection of blood and bone mar-row in lymphomas are under development. Such methods will make it possible to monitor the MRD in the bone marrow and blood in individual patients during induction therapy, and purge the autografts when remaining tumour cells are found.
In summary, our results show that immunomagnetic purging has no adverse effects on haematopoietic reconstitution, and that tumour contamination of the autograft might represent a risk of relapse.
